Regulatory approval

Published by the Health Service Executive. Approved

Treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC).

This is written in the approval document.

Reimbursement

CDS

Citation

Osimertinib Monotherapy, 2024, version number 5, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/6914/353_V5_Osimertinib_Monotherapy.pdf

View API

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations Biomarkers Cancer types Therapies
HSE (1) EGFR p.T790M Non-Small Cell Lung Cancer Osimertinib